Wednesday, October 22, 2014 4:48:36 PM
And as the whole "promised" in 30 days jag is also an illogical leap from what was actually said or implied by Dr. Seymour's statements - that's not making a relevant point either from my perspective.
What I am looking for (although I don't expect to see them in some made-up timeframe like that magical "30-day" statement) are a few milestones to be accomplished that do have relevance to NNVC's corporate future.
I'm waiting to see evidence that a testing contract with a BSL-4 lab has been finalized, and that the appropriate MTA has been signed off on. That's when the Ebolacide2 testing clock starts. Chances are that's going to take 2-ish months to work through even if pieces of the work are undertaken in parallel rather than in series. All this blathering about 30-days or anything else becomes irrelevant at that point as that's when Ebolacide2's clock starts ticking.
I suspect that we'll see movement on this front within the next couple of weeks - but depending on the extent of QC that needs to be done on the newly synthesized ligands and how smoothly it goes it could be sooner or longer.
I'm waiting to see evidence that the Shelton plant is ready to roll. As neither large quantities of GMP/GLP Flucide needed for Clinical Testing, nor large quantities of Ebolacide2 needed for emergency human testing (if the preliminaries merit such a rapid push for potential humanitarian use) in Africa will be practical if 'we' cannot make enough micelle material to keep the testing or the humanitarian use supplied.
I suspect that the Shelton plant will be validated sufficiently to use sometime this Winter - but that's insider information that I don't have and nobody 'out here' officially has either.
The whole '30-day' issue is claptrap.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
- NanoViricides, Inc. to Present at The Inaugural Ef Hutton Global Conference on May 10, 2023 in New York City • GlobeNewswire Inc. • 05/04/2023 10:45:00 AM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM